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ABSTRACT 
 
Purpose: To investigate the effects of mild-to-moderate cystic fibrosis (CF) on the pulmonary 
oxygen uptake (
2OV
 ) kinetics of 7 pediatric patients (13.5 ± 2.8 y) versus 7 healthy matched 
controls (CON; 13.6 ± 2.4 y). We hypothesized that CF would slow the 
2OV
 kinetic response at the 
onset of moderate (MOD) and very heavy (VH) intensity cycling. Methods: Changes in breath-by-
breath 2OV
 , near-infrared spectroscopy-derived muscle deoxygenation ([HHb]) at the m. vastus 
lateralis and thoracic bioelectrical impedance-derived heart rate, stroke volume index (SVI) and 
cardiac index (CI) were measured during repeat transitions to MOD (90% of the gas exchange 
threshold) and VH (Δ60%) intensity cycling exercise. Results: During MOD, the phase II 
2OV
 τ 
(p=0.84; effect size (ES) = 0.11) and overall mean response time (MRT) (p=0.52; ES=0.11) were 
not significantly slower in CF versus CON. However, during VH exercise, the phase II 2OV
 τ 
(p=0.02, ES=1.28) and MRT (p=0.01, ES=1.40) were significantly slower in CF. Cardiac function, 
central O2 delivery (SVI and CI) and muscle [HHb] kinetics were unaltered in CF. However, the 
arterial-venous O2 content difference (C(a-v̅)O2) was reduced during VH at 30 s (p=0.03, ES=0.37), 
with a trend for reduced levels at 0 s (p=0.07, ES=0.25), 60 s (p=0.05, ES=0.28) and 120 s (p=0.07, 
ES=0.25) in CF. Furthermore, ∆C(a-v̅)O2 significantly correlated with the VH phase II 2OV  τ (r= -
0.85; p=0.02) and MRT (r = -0.79; p=0.03) in CF only. Conclusion: Impairments in muscle 
oxidative metabolism during constant work rate exercise are intensity-dependent in young people 
with mild-to-moderate CF. Specifically, 
2OV
 kinetics are slowed during VH but not MOD cycling 
and appear to be mechanistically linked to impaired muscle O2 extraction and utilization.  
 
Keywords: oxidative muscle metabolism; pulmonary disease; near-infrared spectroscopy; oxygen 
delivery; pediatrics.  
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INTRODUCTION 
 
Maximal O2 uptake ( 2OV max) is clinically important in patients with cystic fibrosis (CF), given 
associations with prognosis (26), risk of hospitalization (25) and health-related quality of life (11). 
2OV
 max by definition does not, however, represent the rate at which aerobic energy transfer adapts 
to the changing metabolic demands facing O2 transport and utilization during everyday life. In 
contrast, assessing the dynamic adjustment in pulmonary 
2OV
 [time constant (τ) for the primary 
component (phase II)] at the onset of exercise provides a non-invasive insight into muscle O2 
consumption dynamics (21) and the breakdown of muscle phosphocreatine (PCr) (30, 4). 
Consequently, this parameter can provide insight into the factor(s) mediating muscle metabolic 
function and the integration of the respiratory, cardiovascular and muscular systems at the onset of 
exercise. Compared to healthy children (for a review see (2)), there is limited evidence in young 
people with CF for the 2OV
 kinetic response and its regulating mechanism(s)  
 
Slower 
2OV
 kinetics have been reported in people with CF during incremental (34, 17), pseudo-
random binary sequence (PRBS) (22) and constant work rate (CWR) exercise (19, 1). However, a 
similar 
2OV
  kinetic response to healthy controls (11-15 y) has been documented during intense 
exercise (7). Methodological issues may explain these disparities. Firstly, during incremental and 
PRBS exercise the phase II portion of the 
2OV
 response was not isolated, which is critical to reflect 
the kinetics of muscle O2 consumption (21). Secondly, the CWR exercise study by Hebestreit and 
colleagues (19) did not prescribe work rate within physiologically defined exercise intensity 
domains. Furthermore, semi-recumbent cycling was used which may negate muscle O2 delivery 
during exercise, and a mixed age group of 10-33 y, which would comprise a range of pulmonary 
function characteristics, were tested (19).  
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According to the Fick principle, the rate of adjustment in 
2OV
 is dictated by O2 delivery and 
utilization mechanisms but few studies have applied this to understand how CF modifies the 
2OV

kinetic response to CWR exercise (42). Slower 
2OV
 kinetics in CF have been linked to impaired O2 
delivery (19), inferred from arterial O2 saturation (SpO2%). Although children with CF may present 
with early signs of cardiovascular abnormalities (18, 38, 29), impaired skeletal muscle oxidative 
capacity in CF is reported (30, 34, 40, 15, 12). The near-infrared spectroscopy (NIRS)-derived 
muscle deoxygenation (∆[HHb]) signal provides insight into the ratio of local muscle O2 delivery to 
muscle O2 utilization. Thus, changes in muscle HHb are considered to represent changes in muscle 
O2 extraction dynamics during exercise (e.g. 16). Although it has been hypothesised that more rapid 
muscle HHb dynamics would be evident in the face of reduced central or muscle O2 delivery (16), 
children and adolescents with CF do not appear able to compensate in this manner during 
incremental exercise (30, 34). This raises questions regarding the capacity of CF skeletal muscle to 
increase muscle O2 extraction during exercise, but this has yet to be evaluated alongside 2OV
kinetics during CWR cycling exercise.  
 
The aim of the study was to characterize the pulmonary 
2OV
 kinetic response of children and 
adolescents with mild-to-moderate CF at the onset of moderate (MOD) and very heavy (VH) 
intensity cycling exercise. It was hypothesized that: 1) a longer phase II 
2OV
  τ at the onset of MOD 
and VH exercise would be evident in CF; 2) slower cardiac output (?̇?) and more rapid [HHb] 
kinetics would be evident in CF during MOD and VH exercise; and 3) slower 
2OV
 kinetics would 
relate to reduced ?̇? and altered muscle ∆[HHb] dynamics in the CF group.  
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MATERIALS AND METHODS 
Study Participants. Seven young Caucasian individuals with stable, mild-to-moderate CF (Tables 
1 and 2) and 7 controls (CON) (Table 2) participated. Inclusion criteria comprised a diagnosis of CF 
based on clinical features, an abnormal sweat test (sweat chloride > 60 mmolL-1 / 100 mg sweat) 
and genotyping. Stable pulmonary function within 10% of best in the preceding 6 months and no 
symptomatic increase or weight loss within 2 weeks was also mandatory. Unstable non-pulmonary 
comorbidities and/or acute infection warranted exclusion. Ethics approval was granted by the South 
West NHS Research Ethics Committee. Informed written consent and assent was obtained from 
parent(s)/guardian(s) and participants.  
 
Table 1. Baseline clinical characteristics for the young CF patients upon initiation into the study.  
 
Variable Value (mean ± SD) Range 
CFTR genotype: 
Homozygote ∆F508  
∆F508/ 2184delA 
∆F508/ G55ID 
 
4 
1 
1 
 
 
 
 
∆F508/ P67L 1  
   
Chronic P. Aeruginosa infection
 a “chronic,” n = 1; 
“intermittent,” n = 2 
“free,” n = 3 
“never,” n = 1 
Shwachman score 85 ± 5 80-90 
Northern score
 b 
4 ± 1 3-6 
Pancreatic insufficient n = 7  
CF-related diabetes n = 1  
CF-related liver disease 
IVABs (days in last year) 
n = 1 
11 ± 9 
 
0-24 
 
Values are means ± SD, with the range also displayed where suitable, unless otherwise stated. 
CFTR, cystic fibrosis transmembrane conductance regulator; P. Aeruginosa; Pseudomonas Aeruginosa; Shwachman 
score - scoring 4 separate aspects of the disease profile; general activity; physical examination; nutritional status; and 
chest radiographic findings, using the most recent clinical review information. A total of 100 points represents a perfect 
score of health; IVABs, intravenous antibiotics; 
aAccording to Leeds Criteria, “chronic”, > 50% of the preceding 12 
months were P. aeruginosa culture positive; “intermittent”, ≤50% of the preceding 12 months were P. aeruginosa 
culture positive; “never”, no growth of P. aeruginosa for the previous 12 months, having previously been P. aeruginosa 
culture positive; “free”, P. aeruginosa has never been cultured.   
b
 Provides evidence of radiographic chest findings. Maximum score is 20, with 20 being the most severe.  
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Table 2. Baseline anthropometric, pulmonary function and maximal cardiopulmonary exercise 
testing data for young patients and healthy age- and gender-matched control participants upon 
initiation into the study.  
 
 
Values are means ± SD unless otherwise stated. M, males; F, females; BMI, body mass index; FVC, forced vital 
capacity; FEV1, forced expiratory volume in 1 s; CPET, cardiopulmonary exercise testing; 2OV

max, maximal oxygen 
uptake; FFM, fat-free mass; GET, gas exchange threshold; MRT, mean response time; PPO, peak power output; TTE, 
time to exhaustion; Smax, supramaximal verification phase; SpO2%, arterial oxygen saturation.  
a
According to Stanojevic 
et al. (2009). 
 
 
Experimental protocol 
Participants attended the laboratory five times over a two week period, at a similar time of day and 
separated by 24-48 h. Participants were advised to arrive rested and hydrated, > 2 h postprandial 
and having refrained from caffeine (> 2 h). All exercise was performed on a cycle ergometer (Lode, 
Groningen, The Netherlands or Lode Corival (Pediatric), Groningen).  
 
Visit 1: CPET protocol. Following anthropometric and pulmonary function measurements, a 
combined ramp incremental and supramaximal (Smax) CPET was used to determine 2OV max and the 
gas exchange threshold (GET) (32, 33). This protocol involved an exhaustive ramp incremental (10-
Variable CF 
Mean ± SD 
CON 
Mean ± SD 
p-value ES (d) 
Gender 5 M, 2 F 5 M, 2 F - - 
Age (y) 13.5 ± 2.80 13.6 ± 2.40 0.93 -0.04 
Stature (m)  1.61 ± 0.20 1.62 ± 0.17 0.92 -0.05 
Body mass (kg) 60.7 ± 22.8 52.4 ± 17.8 0.46 0.38 
BMI (kg·m
2
) 22.6 ± 4.5 19.4 ± 2.9 0.14 0.79 
FFM (kg) 49.5 ± 19.9 40.1 ± 12.5 0.30 0.54 
FVC (L) 3.91 ± 1.29 4.08 ± 1.50 0.82 -0.12 
FVC ( % predicted
a
) 106 ± 10 107 ± 17 0.82 -0.11 
FEV1 (L) 3.27 ± 1.00 3.59 ± 1.26 0.61 -0.26 
FEV1 (% predicted
a
) 102 ± 6 110 ± 12 0.17 -0.72 
 
CPET parameters 
- - - - 
2OV
 max (L·min
-1
) 2.08 ± 0.74 2.51 ± 0.91 0.34 -0.49 
2OV
 max  (mL·kg
-1
·min
-1
) 34.30 ± 8.88 47.75 ± 3.56 < 0.01* -1.79 
2OV
 max/FFM (mL·kg
-1
·min
-1
) 51.87 ± 34.90 65.52 ± 24.65 0.42 -0.42 
2OV
  at the GET (L·min
-1
) 1.09 ± 0.31 1.38 ± 0.48 0.20 -0.67 
GET% (% of V̇O2max ) 53.7 ± 6.4 55.2 ± 3.3 0.57 -0.28 
Ramp PPO (W) 162 ± 61 208 ± 86 0.27 -0.58 
Ramp TTE (s) 546 ± 111 729 ± 113   0.01* -1.52 
SpO2% (%) 95 ± 3 98 ± 1   0.04* -1.23 
7 
  
25 W·min
-1
) cycling test with a subsequent Smax (110% peak power output (PPO)) test to 
exhaustion, to confirm a valid 
2OV
 max measurement. Following a 3 min warm-up (20 W), 
participants completed the incremental test to the point of volitional exhaustion, maintaining a 
cadence of 70-80 rpm throughout. Exhaustion was defined as a ≥10 rpm drop in cadence for 5 
consecutive seconds, despite strong verbal encouragement. Active (5 min cycling at 20 W) and then 
passive seated recovery (10 min) then preceded the Smax test. Smax verification consisted of a 3 min 
warm-up (20 W), followed by a ‘step’ transition to a CWR corresponding to 110% PPO. Upon 
volitional exhaustion (defined above), a 5 min active recovery (slow cycling at 20 W) concluded the 
combined CPET session.  
 
Visits 2-5: CWR exercise. For each visit the participants completed MOD and VH CWR exercise 
tests, comprising 6 min unloaded pedalling (10 W), followed by transitions to elicit 
2OV
 amplitudes 
corresponding to 90% GET and Δ60% (60% of the difference between the GET and 
2OV
 max) for 6 
min. This equated to MOD work rates of 58 ± 24 W and 73 ± 35 W for CF and CON, respectively. 
During VH, CF and CON cycled at 121 ± 43 W and 150 ± 64 W, respectively. Thirty minutes rest 
separated the MOD and VH transitions. Each set of MOD and VH transitions was performed on 
separate days, separated by ≥ 48 h and within a 2 week period.  
 
Experimental measures 
Anthropometry and pulmonary function. Body mass (Seca 220; Vogel & Halke, Hamburg, 
Germany) and stature (Seca 220; Vogel & Halke, Hamburg, Germany) were measured to the 
nearest 0.01 kg and 0.01 m. Skinfold measurements (Harpenden; British Indicators, Burgess Hill, 
UK) were used to estimate percentage body fat (37). Forced vital capacity (FVC) and forced 
expiratory volume in 1 s (FEV1) were assessed using spirometry (Micromedical Microloop 3535, 
Numed, Sheffield, UK), and expressed as a percentage predicted using appropriate reference values 
(38).  
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Gas exchange and pulse oximetry. Breath-by-breath changes in gas exchange and ventilation were 
determined using a metabolic cart (Metalyzer 3B Cortex, Biophysik, Leipzig, Germany), which was 
calibrated each test using gases of known concentration and a 3 L syringe (Hans Rudolph, Kansas 
City, MO). Fingertip SpO2% was measured on a beat-by-beat basis at the fingertip using pulse 
oximetry (NONIN, Avant 4000, NONIN Medical Inc., USA). 
 
Near-infrared spectroscopy. A near-infrared spectrometer (Portamon, Artinis Medical Systems) 
was used to non-invasively measure [HHb] at the m. vastus lateralis. Details regarding this system 
have been outlined in our previous work in young people with CF during ramp incremental exercise 
(34). Briefly, this system consists of an emission probe, with three light sources emitting two 
wavelengths of light (760 and 850 nm) and a photon detector. Following cleaning and shaving of 
the area of interrogation, the wireless emitter-detector unit was placed over the muscle belly, 
midway between the greater trochanter and lateral epicondyle of the femur. After marking of the 
placement area, the device was secured with tape (Kinesio
®
 Tex) and a dark elastic bandage to 
minimize extraneous light interference with the near-infrared signal. The intensity of incident and 
transmitted light was recorded at continuously at 10 Hz.  
 
Thoracic Impedance. Beat-by-beat changes in heart rate (HR), SV and ?̇? were measured using a 
bioelectrical impedance cardiography system (PhysioFlow, PF-05, Manatec Biomedical, Paris, 
France) that has previously been used in CF (e.g. 2). This technique uses a high-frequency (75 kHz) 
and low-magnitude (1.8 mA) current across the thorax, to enable changes in thoracic impedance 
during the cardiac cycle to be recorded. Following preparation of the skin sites, electrodes were 
positioned on the forehead, base of the neck and above the supraclavicular fossa, and two 
positioned on the xiphoid process. Another set of two electrodes were used to determine a single 
electrocardiograph signal at the V1 and V6 positions.  
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CPET parameters of aerobic function. The highest 15 s averaged 2OV
 from the ramp and Smax 
tests represented 
2OV
 max (32) and was normalized to fat-free mass (FFM) using the ratio standard 
method. The GET was identified using the V-slope method (5) and confirmed through visual 
inspection of the ventilatory equivalents for 2OV
  and V̇CO2.  
 
Pulmonary 2OV
  kinetics. Breath-by-breath changes in 
2OV
  were analysed using methodology 
previously described by our laboratory (3, 8). Briefly, the four repeat transitions for both MOD and 
VH were linearly interpolated to 1 s, time aligned to exercise onset (i.e., t = 0 s) and ensemble 
averaged. The 1 s averaged V̇O2 response for the MOD and VH conditions for each participant were 
then baseline corrected, by subtracting the mean 2OV
 between -60 and -5 s from the exercise 
response. The duration of phase I was visually assessed to account for the cardio-dynamic 
contribution to the 2OV
 kinetic response. The first 21 ± 3 s and 17 ± 4 s of the MOD data and the 
first 19 ± 5 s and 16 ± 2 s for VH were omitted in CF and CON participants, respectively. The 
phase II portion of the 2OV
 response was then characterised using Equation 1 (GraphPad Prism; 
GraphPad Software, San Diego, CA): 
 
2OV

 (t) = Δ 2OV A  · (1 – e 
– (t –TD)/τ
)                          Equation 1.  
 
 
where 
2OV
 (t), Δ 2OV
  A, TD, and τ represent the value of 2OV at a given time (t), the amplitude 
change in 
2OV
 from baseline to its asymptote, time delay, and the time constant of the response, 
respectively.  
 
The MRT was derived to describe the overall kinetics during both MOD and VH, by constraining 
the TD in Equation 1 to the onset of phase I and fitting to end-exercise. The functional 2OV
 gain of 
phase II was determined by dividing the phase II 2OV
 amplitude by the change in work rate above 
baseline. End-exercise 
2OV
  gain was calculated in a similar manner. For VH exercise, the 
2OV

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slow-component onset and amplitude were determined in line with our previous work (3, 8). 
Briefly, Equation 1 was first fit up to the initial 60 s of exercise and then increased iteratively by 1 s 
to the end of the exercise bout (LabView, v 6.1, National Instruments, Newbury, UK). The best fit 
curve for the phase II portion of the response was established using: 1) a plot of the 
2OV
  τ against 
time, to identify the point at which the influence of the 
2OV
 slow component lengthened the 
estimated τ following an initial plateau; and 2) deviation from an optimal fitting of the model as 
judged by a systematic departure of the model’s residuals. The phase II parameter estimates from 
equation 1 were then resolved by least-squares non-linear regression (GraphPad Prism, GraphPad 
Software, San Diego, CA). The magnitude of the 
2OV
  slow component was calculated as the 
difference between the mean of the final 30 s at 6 min of exercise and the phase II asymptote and 
was expressed in both absolute terms and relative to end-exercise 
2OV
 . 
 
Muscle oxygenation kinetics. NIRS data were collected at 10 Hz, interpolated to 1 s intervals and 
expressed as a change, in arbitrary units (a.u.), from baseline. Subsequently, [HHb] profiles were 5 
s averaged, time aligned to exercise onset and ensemble averaged to yield a single response. The 
dynamics of the primary and slow-component phases of the [HHb] response were modelled in a 
similar manner to 
2OV
 , with slight modification. The exponential-like increase in [HHb] after the 
onset of exercise occurred after a discernible delay. The time at which the exponential-like increase 
in [HHb] commenced was identified as the point of a 1 SD increase above baseline (3). Equation 1 
was then applied to resolve the [HHb] TD and τ following removal of the data preceding the 
exponential-like increase. The [HHb] MRT was calculated by summing TD and τ to provide an 
overall description of the kinetics in the primary phase.  
 
Heart rate, stroke volume, cardiac output and C(a-?̅?)O2. Beat-by-beat changes in HR, SV and ?̇? 
were linearly interpolated to 1 s, time aligned and ensemble averaged to 30 s. The arterial-venous 
O2 content difference [C(a-v̅)O2] was estimated via rearrangement of the Fick equation [C(a-v̅)O2 = 
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2OV
 / ?̇?]. SV and ?̇? were normalized to FFM (12) using the ratio standard method, to determine the 
cardiac index (CI) and SV index (SVI). The ?̇?/
2OV
  ratio was used to provide an index of muscle O2 
availability relative to metabolic rate.  
  
Statistical analyses 
Independent samples t-tests examined mean differences between CF and CON. Additionally, effect 
size [ES (d)] statistics determined the magnitude of the effect, using a pooled SD. The magnitude of 
the difference between variables of interest were explored using ES thresholds of trivial (< 0.2), 
small (> 0.2), moderate (> 0.5), large (> 0.8), and very large (> 1.0) (9). Changes in HR, SV, 𝑄 ̇ and 
C(a-v̅)O2 were analysed using mixed model ANOVA. Significant interactions were followed up 
using independent samples t-tests. Pearson’s correlation coefficients assessed relationships between 
V̇O2 kinetics and mechanistic parameters of O2 delivery and utilization. Statistical analyses were 
performed using SPSS (version 19.0, SPSS, Chicago, IL), with the null-hypothesis rejected at alpha 
level of 0.05.  
 
RESULTS 
Maximal cardiopulmonary exercise testing 
Descriptive characteristics and CPET data are presented in Table 2. There were no differences in 
body size and composition and lung function between CF and CON. 
2OV
 max was reduced in CF 
compared with CON when normalized using body mass but not FFM.   
 
Pulmonary ?̇?O2 kinetics  
The 
2OV
  responses during MOD and VH are presented in Figure 1 and the kinetic parameters in 
Table 3. There was no significant difference in baseline 
2OV
  between the groups for either MOD or 
VH exercise (Table 3). For MOD, CF had no influence on either the phase II τ, TD or MRT. 
However, the phase II 
2OV
  gain was lower in CF. During VH exercise, the 
2OV
  MRT and phase II 
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τ were slower in CF. The phase II TD, amplitude and gain and end-exercise 
2OV
  were not altered in 
CF. A 
2OV
  slow-component manifested in all VH responses, however the amplitude was similar 
between CF and CON.  
  
13 
  
Table 3. Pulmonary oxygen uptake kinetics in CF and CON during MOD and VH exercise.   
 
  
Variable CF 
Mean ± SD 
CON 
Mean ± SD 
 
p-value ES (d) 
Moderate intensity exercise 
 
Baseline 
2OV
  (L·min
-1
) 0.62 ± 0.13 0.68 ± 0.16 0.47 -0.38 
Phase II 
2OV
   τ (s) 25.2 ± 6.7 26.1 ± 8.4 0.84 -0.11 
Phase II 
2OV
   TD (s) 21.7 ± 7.3 14.8 ± 7.1 0.10  0.90 
Phase II 
2OV
  amplitude 
(L·min
-1
) 
0.42 ± 0.20 0.64 ± 0.34 0.16 -0.76 
Phase II 
2OV
  gain (mL·min
-
1
·W
-1
) 
8.6 ± 1.3 10.4 ± 1.4   0.03* -1.21 
2OV
  mean response time (s) 44.6 ± 8.0 41.6 ± 8.9 0.52 0.33 
 
Very heavy intensity exercise 
 
Baseline 
2OV
 (L·min
-1
) 0.68 ± 0.15 0.76 ± 0.19 0.37 -0.46 
Phase II 
2OV
   τ (s) 37.5 ± 10.8 25.1 ± 6.5   0.02* 1.28 
Phase II 
2OV
 TD (s) 14.7 ± 6.1 14.6 ± 3.0 0.96 0.03 
Phase II 
2OV
   amplitude 
(L·min
-1
) 
0.97 ± 0.34 1.26 ± 0.54 0.25 -0.60 
Phase II  
2OV
 gain (mL·min
-
1
·W
-1
) 
8.9 ± 0.8 9.2 ± 1.2 0.51 -0.34 
2OV
  slow-component onset 
(s) 
144 ± 29 117 ± 21 0.07 0.99 
2OV
  slow-component 
amplitude (L·min
-1
)   
0.19 ± 0.15 0.16 ± 0.13 0.74 0.17 
2OV
  slow-component 
relative amplitude (%) 
9.0 ± 6.3 6.7 ± 3.8 0.43 0.40 
End-exercise 
2OV
  (L·min
-1
) 1.83 ± 0.59 2.18 ± 0.83 0.38 -0.46 
End-exercise 
2OV
   gain 
(mL·min
-1
·W
-1
) 
9.9 ± 1.3 10.3 ± 0.9 0.56 -0.30 
2OV
  mean response time (s) 74.6 ± 19.4 51.6 ± 8.3   0.01* 1.40 
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Muscle oxygenation kinetics  
The group mean data for [HHb] and the corresponding kinetic parameters are shown in Figure 2 and 
Table S1 (Supplemental Digital Content 1 – muscle oxygenation kinetics of young CF patients and 
healthy control participants at the onset of moderate and very heavy intensity cycling exercise), 
respectively. The [HHb] response of one CF patient (male, 10 y, ∆F508 homozygote) did not 
display exponential characteristics and was, in addition to their healthy control, excluded from 
[HHb] analyses. There was no difference between CF and CON for any of the [HHb] kinetic 
parameters during MOD or VH exercise. 
 
Heart rate, stroke volume index, cardiac index and C(a-?̅?)O2. 
Group mean HR, CI, SVI and C(a-v̅)O2 dynamics are presented in Figure 3. No significant time by 
disease state interaction effect for SVI was evident during either MOD (p = 0.09) or VH (p = 0.27). 
During VH there was a significant interaction between time and disease state for HR (p = < 0.01), 
with follow-up comparisons identifying a higher HR in CF at 30 s (p = 0.04, ES = 0.21). There was 
a significant main effect for disease state (p = 0.01) for CI to be lower in CF during MOD but not 
VH (p < 0.05). There was a time by disease state interaction (p = 0.03) for C(a-v)O2 during VH 
(Figure 3d), with extraction significantly reduced in CF at 30 s (p = 0.02, ES = 0.37) and a trend 
towards reduced values at 0 s (p = 0.07, ES = 0.25), 60 s (p = 0.05, ES = 0.28) and 120 s (p = 0.07, 
ES = 0.25). ?̇?/
2OV
  was not different between the groups for either intensity (p > 0.05).  
 
Relationships between 
2OV
  kinetics and mechanistic parameters 
During MOD, the phase II 
2OV
  τ significantly correlated with ∆[HHb] (r = 0.84; p = 0.04) in CF, 
whilst the MOD 
2OV
  MRT correlated with ∆SVI in CON (r = -0.81; p = 0.03). During VH, the 
∆C(a-v̅)O2 significantly correlated with the phase II 2OV  τ (r = -0.85; p = 0.02) and MRT (r = -0.79; 
p = 0.03) in CF. Furthermore, ∆?̇?/∆
2OV
  significantly correlated (r = 0.78; p = 0.04)  with the phase 
II 
2OV
  τ in CF during VH exercise.     
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DISCUSSION  
This is the first study to examine the dynamics of 
2OV
  in children and adolescents with mild-to-
moderate CF at the onset of MOD and VH intensity cycling exercise, relative to adjustments in 
central O2 delivery and localized muscle (m. vastus lateralis) O2 extraction. The novel and original 
findings from this study are: 1) 
2OV
  kinetics were slowed in CF during VH but not MOD; 2) no 
differences in muscle [HHb] kinetics were found between CF and CON during MOD and VH 
exercise; 3) during VH exercise only, C(a-v̅)O2 was reduced in CF within the initial 60 s of exercise 
onset, and 4) the change in C(a-v̅)O2 during VH exercise was significantly correlated with the phase 
II 
2OV
  τ and MRT in CF. Collectively, these findings support the notion that impaired muscle 
oxidative metabolism in young CF patients is dependent on the intensity of exercise and principally 
limited by muscular factors, which limit the extraction and utilisation of O2 during VH exercise  
 
Contrary to our hypothesis, neither the phase II or overall 
2OV
  kinetics were slowed during MOD 
intensity cycling in young people with CF. This is consistent with early observations in similarly 
aged patients (11.1-15.3 y) with mild airway obstruction during 6 minutes cycling at 1.7 W·kg
-1
 (7). 
In contrast, two studies have documented slower 
2OV
  dynamics during exercise in patients with CF 
(22, 19), however methodological issues may explain this disparity. Kusenbach et al. (22) employed 
PRBS exercise which fails to isolate phase II of the 
2OV
  response. Although Hebestreit et al. (19) 
utilised CWR exercise and isolated phase II, work rate was not prescribed within physiologically 
defined intensity domains (18). This process meant patients were likely to be exercising across the 
MOD-severe intensity domains which, if the intensity was above the GET, would be consistent with 
our present findings of slowed 
2OV
  kinetics during VH exercise. Hebestreit and colleagues also 
used semi-supine exercise (19), which may reduce muscle perfusion
 
and slow 
2OV
  dynamics (20). 
Finally, the combination of adult and paediatric patients (10-33 y) could have contributed to slow 
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2OV
  kinetics, since slower phase II kinetics were recently documented in adults with more 
advanced CF (22 ± 4 y) during submaximal cycling (1). 
 
An interesting finding in this study was that the influence of CF on oxidative muscle metabolism 
appears to be intensity dependent. This is based on the finding that the phase II 
2OV
  τ and MRT 
were slowed only during VH exercise and the ES was very large (> 1.0). This is of clinical 
importance, since slower 
2OV
  kinetic response will incur a greater O2 deficit and a greater degree of 
substrate-level phosphorylation (increased lactic acid and PCr breakdown) and the accumulation of 
fatigue-inducing metabolites (e.g., inorganic phosphate and hydrogen ions), which may impair 
exercise tolerance especially during VH exercise in young people with CF. An exercise intensity 
dependence to the impaired oxidative metabolism in CF corresponds with earlier observations in 
adolescent patients during a 90 s high-intensity exercise challenge performed within a 
31
Phosphorous Magnetic Resonance Spectroscopy scanner environment, but not shorter duration or 
less intense exercise (39). This may reflect the greater physiological challenge to mitochondrial 
aerobic metabolism elicited by higher intensities. 
 
The longer phase II 
2OV
  τ of patients with CF (10-33 y; FEV1: 37-98% predicted) has previously 
been linked to inadequate O2 delivery, inferred by a significant relationship with SpO2 (19). In the 
current study, bulk blood flow, as inferred using the CI (?̇?), was not profoundly altered during 
either MOD or VH exercise in CF. Furthermore, 
2OV
  kinetics were not mechanistically linked to 
the CI and SVI dynamics in this group of patients, despite previous reports that early signs of 
cardiac dysfunction may present in paediatric patients with CF (18, 34). Although CFTR is 
involved in the regulation of cardiomyocyte contraction (36) and gene mutation targeted therapies 
have been shown to increase SV in adolescents with CF (35), the current findings indicate that 
central O2 delivery does not principally limit 2OV  kinetics in young CF patients. This is further 
supported by research demonstrating that elevating SpO2 through the inspiration of hyperoxic gas 
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does not improve the kinetics of 
2OV
  in patients with CF (22). However, it must be acknowledged 
that only central indices of O2 delivery, which are relatively poor indicators of O2 delivery at the 
local muscle level during exercise (24), were obtained in these studies.  
 
However, considering the findings in the present study, the impaired 
2OV
  kinetics during VH 
exercise were related to the capacity of skeletal muscle to extract and utilize O2. For the first time, 
this study investigated the [HHb] dynamics of young patients with CF during CWR exercise, with 
similar kinetics observed between the groups. If muscle O2 availability was limiting oxidative 
metabolism in CF, a compensatory acceleration in the rate of O2 extraction would be expected (16). 
This was not observed in the present study and this finding corresponds with earlier studies during 
incremental exercise using both NIRS (34) and respiratory mass spectroscopy (30). Whilst this 
finding shows that the rate of O2 extraction taking place was not different in CF compared to CON, 
[HHb] does not reflect the amount of O2 extraction taking place. This can be physiologically 
interpreted from the C(a-v̅)O2 parameter.  
 
Interestingly, we observed a significant reduction in C(a-v̅)O2 in CF during the early stages of VH 
exercise (see Figure 3D), which corresponds with the timing of the phase II portion of the 
2OV

response, although the corresponding effect sizes were small. Furthermore, ∆C(a-v̅)O2 significantly 
correlated with the phase II 
2OV
  τ and MRT during VH in CF only. These findings suggest that the 
amount of muscle O2 extraction and utilization is impaired in this patient group near the onset of 
exercise and is mechanistically linked to the dynamics of 
2OV
 . These findings support previous 
speculations regarding a peripheral limitation slowing V̇O2 kinetics in patients with CF (19). This 
O2 extraction and utilization impairment may be explained by structural and functional changes in 
skeletal muscle that are evident in CF (40, 12, 23). Although a recent study has provided conflicting 
data (41), slower post-exercise PCr recovery kinetics, measured using 
31
Phosporous magnetic 
resonance spectroscopy, suggest impaired muscle oxidative capacity in both the  m. vastus lateralis 
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and forearm muscle (40, 12). More recently, reduced local muscle oxidative capacity was inferred 
from the recovery of m. vastus lateralis O2 consumption following 15 s of electrical stimulation and 
subsequent repeated transient arterial occlusions (15). Evidence of CF-specific muscle metabolic 
abnormalities (lower adenosine triphosphate concentration ([ATP]) and ATP:PCr at rest and 
significantly higher end-exercise pH values) (40) also support the present suggestions regarding a 
muscular abnormality in this patient group.   
 
The cause(s) of an intramuscular impairment in CF are currently unknown, although several factors 
have been proposed. Reduced antioxidant capacity, arising from systemic inflammation and/or 
oxidative damage, may lower mitochondrial efficiency (39). However, it may also be a consequence 
of the CFTR genetic mutation. CFTR is expressed in skeletal muscle cells (23) and in vitro study of 
leucocyte mitochondria in patients with CF demonstrates that properties of complex I of the 
respiratory chain are significantly altered (10). Furthermore, absence of CFTR from skeletal muscle 
has been shown to dysregulate calcium homeostasis, augment inflammatory or atrophic gene 
expression signatures and increase diaphragm weakness (14). Conversely, improving CFTR 
(dys)function using Ivacaftor shows potential to improve aerobic exercise function in adolescents 
with CF (35). Recent evidence that vascular endothelial (dys)function is associated with a poorer 
2OV
 max in young people with CF (28, 29) has been reported. However, the impact of impaired 
vascular function on the ability of people with CF to deliver O2 locally for extraction also requires 
further investigation.   
 
Whilst the present study provides the first robust investigation of the 
2OV
  kinetic response in young 
CF patients, there are a number of limitations to be considered. NIRS exercise measurements in this 
population have recently been outlined in greater detail elsewhere (34), however include a 
restricted, heterogenous and superficial area of interrogation and possible inter-site variation in 
[HHb]. To minimize these limitations, the NIRS device was secured to the same anatomical region 
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of all participants to eradicate inter-individual regional differences within the m. vastus lateralis and 
[HHb] responses were standardized to the total [HHb] amplitude to provide a physiologic 
normalisation (6). Furthermore, adipose tissue thickness at the site of interrogation was not 
measured, which precludes comparing amplitude changes between the groups. Although the utilized 
thoracic impedance device has been validated in CF patients (27), this technique provides a non-
invasive estimate of SV and   more detailed echocardiography indices of ventricular function, in 
addition to further measurements of vascular endothelial function would be insightful. Further, 
since CFTR is expressed in human vasculature and vascular endothelial dysfunction has been 
related to 
2OV
 max in young CF patients (28, 29), contribution to altered 2OV  kinetics warrants 
further investigation. Finally, since muscle fibre type composition and recruitment were not 
measured herein, discrepancies in fibre type composition and recruitment strategies between the 
groups cannot be excluded.  
 
These findings help us to further understand how young people with CF respond to the increased 
metabolic demand during activities of daily living and fatiguing exercise. Whilst children and 
adolescent with mild-to-moderate CF appear to respond in a similar manner to their healthy 
counterparts during MOD exercise, the slowed 
2OV
  kinetics at the onset of exercise above the GET 
may well be linked to reduced exercise tolerance, which should be considered by the exercise 
practitioner when considering exercise prescription strategies for this patient group. Promisingly, 
identifying the rate limiting determinant(s) of pulmonary 
2OV
  kinetics in individuals with CF may 
provide viable targets for intervention.  
 
To conclude, this study demonstrates that the 
2OV
  kinetics of paediatric patients with CF are 
slowed during VH but not MOD intensity cycling exercise. Impaired skeletal muscle oxidative 
metabolism in this patient group is intensity dependent and appears to be mechanistically linked to 
an intrinsic intramuscular impairment which limits O2 extraction and utilization. Identifying the rate 
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limiting determinant(s) of pulmonary 
2OV
  kinetics in individuals with CF may provide viable 
targets for intervention in the future.  
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Supplemental Digital Content 1.doc  Muscle oxygenation kinetics of young CF patients and 
healthy control participants at the onset of moderate and very heavy intensity cycling exercise.   
 
Figure 1. Mean 
2OV
  profile for cystic fibrosis (○ white circles) versus healthy (● black circles) 
children and adolescents during moderate (A, C) and very heavy (B, D) intensity cycling exercise. 
Figures C and D provide the normalized to end-exercise so that the differences in the phase II 
region of the V̇O2 response can be observed. The vertical dotted line illustrates the onset of exercise 
from a 10 W baseline. Data are presented as 5-s averages 
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Figure 2. Mean [HHb] profile for cystic fibrosis (○ white circles) and healthy (● black circles) 
young people during moderate (A,C) and very heavy (B,D) intensity cycling exercise. Figures C 
and D provide the normalized to end-exercise so that the differences in the phase II region of the 
[HHb] response can be observed The vertical dotted line denotes the onset of exercise from a 10 W 
baseline. Data are presented as 5-s averages. 
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Figure 3. Group mean heart rate (A), fat-free mass (FFM) normalized stroke volume (B), FFM 
normalized cardiac output (C) and FFM normalized arterial-venous O2 content difference [C(a-v)O2] 
(D) dynamics of young cystic fibrosis patients (○ white circles) and healthy age- and gender-
matched controls (● black circles) during moderate (1) and very heavy (2) intensity cycling 
exercise. The vertical dotted line denotes the onset of exercise from a 10 W baseline. Data are mean 
and SD and 30-s averages. * denotes P < 0.05, i.e. significant mean difference between CF patients 
and healthy controls, whilst 
+
 denotes a statistical trend (p = 0.07).  
 
